Chimerix (CMRX) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Chimerix Announces First Quarter Financial Results
May 11, 2015 7:30 AM EDTDURHAM, N.C., May 11, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results for the first quarter 2015.
M. Michelle Berrey, MD, MPH, President and CEO of Chimerix, said, "The first quarter of 2015 allowed us to make significant progress in our development program for brincidofovir. We are close to completing enrollment of our Phase 3 SUPPRESS trial for the prevention of cytomegalovirus (CMV) in stem cell transplant recipients. We continue to rapidly enroll patients in our Phase 3 AdVise study for the... More
